2.18
+0.14(+6.86%)
Currency In NaN
| Previous Close | 2.04 |
| Open | 2.05 |
| Day High | 2.18 |
| Day Low | 2.05 |
| 52-Week High | 17.31 |
| 52-Week Low | 1.47 |
| Volume | 293,786 |
| Average Volume | 233,338 |
| Market Cap | 53.11M |
| PE | -0.36 |
| EPS | -6.04 |
| Moving Average 50 Days | 1.92 |
| Moving Average 200 Days | 6.6 |
| Change | 0.14 |
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 8:05 PM GMT
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune dise
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
GlobeNewswire Inc.
May 13, 2025 8:05 PM GMT
64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of response for AlloNK + rituximab no
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 8:35 PM GMT
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalabi